I. Tumors as a System within the Host System
Tumors are an integrated system of interacting malignant cells, cancer stem cells, and stromal components. Key tumor cell interaction partners include leukocytes, fibroblasts and vascular and lymphatic endothelial cells. The majority of the leukocytes within the tumor microenvironment are macrophages, but lymphocytes, granulocytes and dendritic cells are also present. These cells are attracted into the tumor system by chemokines and often can become commensal in performing tumor-promoting or -protective functions. Alternatively, these cells can be rendered nonresponsive (anergic) or driven into apoptosis. Tumor-associated macrophages perform a dominant role in supporting tumor progression by producing growth factors that support tumor growth, e.g. EGF [3, 4] ; angiogenic factors such as VEGF and angiogenic chemokines chemokines, such as CXCL12 [35] , to stimulate tumor growth and promote angiogenesis and to modulate immune cell function. Carcinoma-associated fibroblasts are also stimulated by tumor cells to express aromatase, a component of the estrogen biosynthetic pathway, resulting in estrogen production at the tumor site and stimulation of tumor cell proliferation [36] [37] [38] [39] . Tumor cells and various stromal cells including fibroblasts and immune cells interact with endothelial cells via various adhesion molecules and chemoattractants to attract endothelial progenitor cells and to promote angiogenesis, tumor growth, infiltration of further immune cells and migration of tumor cells to new sites [40, 41] . Tumors also appear to induce neoneurogenesis, and thereby interact with nerve cells, which produce neurotransmitters to stimulate proliferation and migration of malignant cells [42, 43] .
The complex structural network of the tumor system and the vital interactions of tumor cells with stromal and immune cells highlight the need for a cellular systems biology approach to cancer diagnostics, which combines multiplexed biomarker panels with informatics tools to produce a systemic readout relevant to patient prognosis.
II. Current Tools for Patient Stratification and Diagnostics in Breast Cancer
The current clinical diagnostic tools for breast cancer are valuable for patient stratification and for predicting risk of recurrence, disease-free survival and responses to therapy. with metastatic breast cancer [51] .
While these tests are valuable, the cellular systems biology approach of assaying multiplexed, functional biomarkers to produce a functional readout of the tumor system will likely become a powerful improvement to these clinical tools. The multiplexing of key tumor process biomarkers to produce a functional readout of the tumor system will enable the creation of classifiers to stratify patients according to clinical phenotype and subtype, and to assess risk of recurrence, outcome and to predict response to therapy with higher specificity and sensitivity on a continuous scale. This cellular systems biology approach has recently been successfully applied to cytotoxicity profiling [2] . The goal is to choose the optimal panel of functional biomarkers employed in a multiplexed profile, coupled with classifier software to translate data sets into indices that can be used for patient stratification and diagnostics.
III. Current Unmet Needs in Breast Cancer Patient Stratification and Diagnostics
Although the current diagnostic tools are valuable, over 40,000 women die of breast cancer each year in the US alone [52] . There is clearly a need for improved diagnostic tools that are highly sensitive and specific to stratify patients and predict risk of recurrence and therapeutic sensitivities on a continuous scale to aid individualized decision making for the treatment of breast cancer patients. There is also a requirement for predictive tools to guide therapy choices for the subgroup of 'triple-negative' breast cancer patients whose tumors are negative for ER, PR and HER2/neu. Specific molecular targets for this subgroup have not been identified and hence directed therapies are unavailable. Triple-negative tumors may have higher sensitivity to chemotherapy than ER + and HER2/neu-amplified tumors, however, as a group these patients have poor prognosis and need accurate predictors of therapy response to ensure the most appropriate firstline treatment is chosen.
IV. Breast Cancer Biomarkers and Options for Measuring Cellular Systems Parameters
Many breast cancer-associated biomarkers with prognostic or predictive value have been described. These can be divided into categories relating to their role in the tumor system or their utility in breast cancer patient stratification and are summarized in Table I .
The rationale for measuring functional biomarkers in intact tissues by automated light microscopy is based on the findings for many biomarkers that the protein level, activation status, cellular localization and tissue localization are important parameters relevant to their use as biomarkers in cancer. Examples for each of these parameters are discussed below:
i) Protein Level
Several cancer biomarkers are downregulated at the protein level without changes in gene
expression. An example is the CD3ζ chain of the T cell receptor signaling complex, an immune biomarker in cancer. Upon ligation of the T cell receptor, tyrosine kinases p56 lck and p59 fyn phosphorylate CD3ζ, triggering further activation of kinases ZAP-70 and Syk, resulting in activation of NF-κB [53] . In cancer patients, CD3ζ expressed by T cells in tumors, draining lymph nodes and blood is degraded at the protein level without alteration at the mRNA level, which contributes to general anergy of T cells in cancer patients [54, 55] . This is associated with several tumor-related activities: i) tumor-secreted soluble factors that may activate intracellular peptidases in T cells or directly degrade CD3ζ protein [55] , ii) chronic stimulation of immune cells in cancer leading to accumulation of terminally differentiated effector cells in which CD3ζ
is replaced by FcRγ, iii) apoptosis of immune cells via interaction with death ligands on the surface of tumors or on tumor microvesicles in the sera [56, 57] , iv) reactive oxygen intermediates produced by activated macrophages or granulocytes [58] and v) interactions with myeloid suppressor cells [59] . Another immune biomarker in cancer that is downregulated at the protein level is NKG2D, a natural cytotoxicity receptor that is expressed on natural killer (NK) cells and T cells. NKG2D is endocytosed and degraded after interaction with NKG2D ligands such as MICA and UL-16 binding proteins that are overexpressed on the surface of tumor cells and on tumor-derived microvesicles [60] [61] [62] .
ii) Activation Status
Biomarkers whose protein level or function is more relevant to patient prognosis and response to therapy than the mRNA level include NF-κB, which is constitutively activated in various cancer types and is associated with aggressive forms of inflammatory breast cancer [63] . The activated state of NF-κB is maintained by autocrine loops of cytokines and growth factors expressed by tumor cells and stromal cells, and many NF-κB-target genes are also cancer biomarkers [64, 65] .
The activation state of signal transduction and activation of transcription (STAT) proteins is also relevant to outcome in breast cancer. High levels of phosphorylated STAT1, STAT3 and STAT5a/b have been correlated with good survival in breast cancer patients, and loss of phosphorylated STATs is observed with disease progression [66] [67] [68] . Many apoptosis-related cancer biomarkers have been described and increased levels of apoptosis within breast tumors are correlated with higher tumor grade and poor outcome [69] . The activation status of these apoptosis biomarkers may be more relevant than their mRNA expression, as shown by the association of the activated and precursor forms of caspase 3, but not the mRNA level, with higher rates of apoptosis in tumors and poor survival in breast cancer [70, 71] .
iii) Cellular Localization
For many cancer biomarkers both their expression and their cellular localization are relevant to prognostic and predictive value. An example is β-catenin, which is involved in cell-cell adhesion and wnt signaling and is regulated by phosphorylation. Mutation of β-catenin is very rare in breast cancer, however, loss of membrane localization of β-catenin and accumulation of phosphorylated β-catenin in the nucleus is strongly associated with poor outcome in breast cancer [72, 73] . p21 is a key regulator of the cell cycle and survival. Nuclear localization of p21 is strongly correlated with the inhibitory effect of p21 on cell growth, whereas cytoplasmic localization is associated with the p21-mediated protection of cells from apoptosis [74] [75] [76] . Both cytoplasmic location and raised levels of phospho-p21 are associated with poor overall survival in breast cancer [77, 78] . The chemokine receptor CXCR4 is a well-established biomarker of tumor cell migration and metastasis in various cancer types [79] . In breast cancer, cytoplasmic CXCR4 in tumor cells has been associated with tumor aggressiveness and positive-lymph nodes, whereas nuclear expression of CXCR4 has been associated with negative-lymph nodes and disease stage [80, 81] .
iv) Tissue Localization
Measurement of certain cancer biomarkers requires preservation of the tissue structure, which is lost in diagnostic approaches that digest tissue to extract cells, proteins or nucleic acids. The morphology of the nucleus, particularly large nuclear area, and also DNA mass in tumor cells have been described to have prognostic power in breast cancer [82] . Nuclear morphology can be in tumor cell nests and stromal areas, whereas mature DCs are confined to peritumoral areas [83, 84] . The localization of CD4 T cells has also been shown to be relevant to prognosis in cancer; stromal localization, rather than tumor cell nest localization in tumors is associated with improved patient outcome [85] .
v) Cell Type Enumeration
An additional and important advantage of immunostaining-microscopy-based approaches to cancer diagnostics is in the enumeration of cell types that are relevant to patient outcome, particularly for those cell types that require multiple biomarkers for identification. 
V. State-of-the-art of Multiplexing Biomarkers in Tissues for Greater Predictive Power
Individual biomarkers contain only limited predictive information of the activity of the network or system in which they function. A more accurate assessment of the disease state in breast cancer may be made by simultaneous measurement of multiple biomarkers representing various key processes in the whole tumor system. This has been demonstrated for various combinations of biomarkers in cancer. p21 Cip/WAF1 and HER2/neu are functionally related in breast cancer. p21
is a downstream substrate of the AKT pathway, which is activated by HER2/neu.
Phosphorylation of p21 by AKT results in cytoplasmic localization of p21, which suppresses the p21-mediated growth inhibition that occurs when p21 is located in the nucleus, and allows its function in the cytoplasm in protecting tumor cells from apoptosis [75, 76] . The combined measurement of phosphorylated-p21 and HER2/neu has been shown to enable stratification of breast cancer patients with HER2/neu-amplified tumors to more precisely predict five-year survival, with high HER2/neu and cytoplasmic phosphorylated-p21 correlating with lowest patient survival and nuclear p21 correlating with low levels of HER2/neu and improved survival [77] .
For ER + tumors, the combination of immunostaining for p53, NDRG1, CEACAM5, SLC7A5
and HTF9C has been demonstrated to distinguish breast cancer patients with poor, moderate and good outcomes and may be an improvement on the standard of care biomarkers ER and PR [89] .
A combination of multiple signaling protein activation profiles has also been shown to have high predictive power for breast cancer. The multiplexed analysis of the phosphorylated forms of HER2/neu, ER, EGFR, MAPK, p70S6K and IGFIR/In was shown to predict breast cancer patient survival and the same combination without IGFIR/In could be used to predict response to the combination of cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy [90] .
VI. Applying the Cellular Systems Biology Approach to Cancer Patient Stratification and Diagnostics
The application of the cellular systems biology approach to cancer diagnostics is illustrated in be assessed using multivariate statistical algorithms to determine the prognostic or predictive value of biomarkers in various combinations. Classifiers can be created to stratify patients according to risk of recurrence, progression-free survival and survival at specific time intervals (five, ten, twenty years), overall survival and responses to various therapies. Classifiers can then be validated in large independent tissue microarray cohorts of patient samples to determine whether the optimal panel of biomarkers that gives a systems readout of the tumor can be used to make clinically useful prognoses and predictions for individual patients.
Summary
In summary, the cellular systems biology approach to breast cancer patient stratification and diagnostics has the potential to make significant improvements on current single biomarker and multigene approaches by producing a readout of the function of key processes of the tumor system. The combination of multiplexed functional biomarkers and informatics tools will hasten the development of specific and sensitive diagnostic tools to more accurately stratify patients with breast cancer and to assess risk of recurrence, survival and to predict responses to specific therapy options. Figures   Fig. (1) . The series of processes involved in the cellular systems biology approach to patient stratification and diagnostics for breast cancer. 
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